BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

...a receptor tyrosine kinase (RTK) whose constitutive activation is know to drive other cancers. The RET-NCOA4...
...tyrosine kinase 3 KRAS - K-Ras MAP2K1 (MEK1) - MAP kinase kinase 1 NCOA4 - Nuclear receptor coactivator 4...
BioCentury | Jun 7, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Three multigene signatures could predict survival in breast cancer patients. In 2,333 patients, genetic profiling of tumor samples identified associations between expression patterns in a panel of 12 genes -- including adenosine...
BioCentury | Apr 21, 2016
Distillery Therapeutics

Therapeutics: Nuclear receptor coactivator 3 (NCOA3; SRC3; AIB1)

Cancer INDICATION: Breast cancer; cancer In vitro testing, cell culture and mouse studies identified a small molecule inhibitor of NCOA3 that could help treat triple-negative breast cancer (TNBC). Screening of a small molecule library, in...
BioCentury | Sep 10, 2015
Distillery Therapeutics

Therapeutics: Nuclear receptor coactivator 1 (NCOA1; SRC1); NCOA2 (SRC2); NCOA3 (SRC3; AIB1)

Cancer INDICATION: Cancer In vitro and mouse studies suggest co-stimulating NCOA1 , NCOA2 and NCOA3 could help treat cancer. In multiple human cancer cell lines, a small molecule research compound that stimulated NCOA1, NCOA2 and NCOA3...
BioCentury | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

A team from the Baylor College of Medicine has treated endometriosis in mice by blocking a pathway that produces a fragment of nuclear receptor coactivator 1 in endometrial tissue. 1 Now, small molecule inhibitors are...
BioCentury | Jun 14, 2012
Distillery Therapeutics

Indication: Genitourinary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Genitourinary disease Endometriosis Nuclear receptor coactivator 1 (NCOA1; SRC1) Patient sample and mouse studies suggest inhibiting an SRC1 fragment could help treat endometriosis. Endometriotic tissue derived...
BioCentury | Jan 8, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Breast cancer Nuclear receptor coactivator 1 (NCOA1; SRC1) A study in mice suggests that blocking SRC1 expression may be useful...
BioCentury | Jan 8, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Breast cancer Nuclear receptor coactivator 1 (NCOA1; SRC1) A study in mice suggests that blocking SRC1 expression may be useful...
BioCentury | Jan 8, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Breast cancer Nuclear receptor coactivator 1 (NCOA1; SRC1) A study in mice suggests that blocking SRC1 expression may be useful...
BioCentury | Dec 18, 2008
Distillery Therapeutics

This week in therapeutics

The Distillery: Therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Von Gierke's disease Glucose-6-phosphatase catalytic subunit (G6PC; G6Pase); nuclear receptor coactivator 2 (NCOA2; SRC2); RAR-related orphan receptor-a (RORa) Studies in mice...
Items per page:
1 - 10 of 11